University of Texas System

Third Wave Technologies, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Lin Ji

Jack A Roth

Hatim T Allawi

Victor I Lyamichev

Jeff G Hall

Bruce P Neri

Peggy S Eis

Michael W Kaiser

Zbigniev Skrzypczynski

Andrew A Lukowiak

Marilyn C Olson-Munoz

Sarah Olson

Hon Ip

LuAnne Chehak

Christian Tor Bartholomay

Tsetska Y Takova

Michelle Curtis

James J Schaefer

Natalie E Lyamicheva

WuPo Ma

Lisa C Thompson

Kevin L Vedvik

Brad T Argue

John Dorrance Minna

Robert W Kwiatkowski, Jr

Michael I Lerman

Gabriel Lopez-Berestein

Ralph B Arlinghaus

Bingliang Fang

Bulent Ozpolat

Jacki Lin

Tong Sun

Robert W Kwiatkowski

Timothy J McDonnell

Stephen G Swisher

Elizabeth M Bruckheimer

Mona G Sarkiss

Bruce N Neri

Jr Robert W Kwiatkowski

Sarah M Olson

Hon S Ip

Michelle L Curtis

John Minna

Natalie E Lyamichev

Wupo Ma

Hatim Taysir Allawi

Luanne Chehak

A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.

Methods and compositions for TUSC2 immunotherapy

Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.

Chromosome 3p21.3 genes are tumor suppressors

A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.

Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

Promoters that include a tissue-selective promoter sequence and a second promoter sequence operatively coupled to the tissue-selective promoter sequence, wherein the second promoter sequence includes a minimal viral promoter sequence, are disclosed. Nucleic acids and compositions that include these promoter sequences are also disclosed. Also disclosed are methods of improving the function of a tissue-selective promoter, involving operatively coupling a tissue-selective promoter sequence with a second promoter sequence that includes a minimal viral promoter sequence. Also disclosed are methods of delivering a gene into a cell, methods of treating a subject with a hyperproliferative disease, and methods of imaging a cell that involve use of the novel promoter sequences set forth herein.

hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes

The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5' nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

RNA detection assays

Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.

Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

Growing community of inventors

Sugar Land, TX, United States of America

Lin Ji